FDA advisory committee considers two LDL-lowering drugs this week

An FDA advisory panel is considering two drugs that lower low-density lipoprotein cholesterol, the Wall Street Journal reports. The injectable medications (evolocumab and alirocumab) are proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and are expected to be used in patients who cannot tolerate statins or who failed with previous statin therapy.